In immunogenic tumors, such as melanoma, the interferons released by tumor‐infiltrating T cells trigger the inducible expression of PD‐L1 by cancer cells, thereby inhibiting the antitumor immune response in a process known as ‘adaptive immune resistance’ (Ribas, 2015). The gene discussed is CD274; the disease is cancer.